Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
Jan 06, 2016 |
referred to health |
Jan 27, 2015 |
referred to health |
Senate Bill S2623
2015-2016 Legislative Session
Sponsored By
(D, WF) 28th Senate District
Archive: Last Bill Status - In Senate Committee Health Committee
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Delivered to Governor
- Signed By Governor
Actions
co-Sponsors
(D, WF) Senate District
(D, WF) 21st Senate District
(D, WF) Senate District
(D, WF) 29th Senate District
2015-S2623 (ACTIVE) - Details
- Current Committee:
- Senate Health
- Law Section:
- Public Health Law
- Laws Affected:
- Amd ยง206, Pub Health L
- Versions Introduced in Other Legislative Sessions:
-
2009-2010:
S3592
2011-2012: S909
2013-2014: S3428
2017-2018: S3999
2015-S2623 (ACTIVE) - Sponsor Memo
BILL NUMBER:S2623 TITLE OF BILL: An act to amend the public health law, in relation to requiring a cost/benefit analysis of pharmaceutical advertising and promotional expenses PURPOSE OR GENERAL IDEA OF BILL: To require the state Department of Health to collect information on pharmaceutical company expenditures incurred in the marketing of prescription drugs and to report to the governor and the legislature the impact of these expenditures on drug utilization, health insurance premiums, and other matters. SUMMARY OF SPECIFIC PROVISIONS: Section one sets out the legislative intent of this measure. Section two adds a new paragraph (v) to subdivision 1 of section 206 of the Public Health Law to require the commissioner of the Department of Health (DOH) to conduct a cost/benefit analysis of the advertising and promotional activities associated with the provisions of prescription drugs in New York State. In performing this function, the commissioner is directed to collect information from pharmaceutical companies (and pharmaceutical companies are directed to provide such information), related to advertising, marketing and so-called "drug detailing" activities, including: 1) funds spent on health care professionals,
2015-S2623 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 2623 2015-2016 Regular Sessions I N S E N A T E January 27, 2015 ___________ Introduced by Sens. KRUEGER, HASSELL-THOMPSON, PARKER, SERRANO -- read twice and ordered printed, and when printed to be committed to the Committee on Health AN ACT to amend the public health law, in relation to requiring a cost/benefit analysis of pharmaceutical advertising and promotional expenses THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Legislative intent. The legislature finds and declares as follows: (1) More than almost all other consumer purchases, the purchase of medications has a direct, discernible impact on the health, life and pocketbooks of New York state citizens. (2) A substantial and growing portion of the price of prescription drug products and their cost to consumers and the state is represented by advertising, particularly direct-to-consumer advertising through mass media, company advertising and promotional activities through the education of the personnel of managed care plans, pharmaceutical benefits management companies, hospi- tals and clinics and health care professionals by means of salespersons' detailing, seminars and conferences, and indirect advertising and promotion to health care professionals and their staffs and the person- nel of managed care plans, and pharmaceutical benefits management compa- nies, hospitals and clinics through entertainment, meals, travel, trips, promotional items, free samples and free supplies, all of which also include the salaries of the growing legions of drug representatives and salespersons. (3) There has been marked increase in spending by pharma- ceutical companies for direct-to-consumer advertising since the liber- alization of federal regulations governing these practices in 1997. (4) Researchers have indicated that assumptions of the amount of advertising are based on extrapolation from data in the public domain since they were unable to obtain data directly from the pharmaceutical companies. (5) Pharmaceutical companies claim that advertising dollars are well EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD03353-01-5
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.